2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Rimas V. Lukas, MD, discusses the efficacy of eflornithine plus lomustine in recurrent IDH-mutant anaplastic astrocytoma per 2021 WHO diagnostic criteria.
Rimas V. Lukas, MD, neuro-oncologist, associate professor, Neurology, Northwestern University Feinberg School of Medicine, discusses key efficacy data and implications from the phase 3 STELLAR trial (NCT02796261) evaluating eflornithine plus lomustine vs lomustine in patients with recurrent IDH-mutant anaplastic astrocytoma per 2021 World Health Organization diagnostic criteria.
Related Content: